COMPOSITIONS AND METHODS COMPRISING HEMP EXTRACT FOR THE TREATMENT OF ANIMALS IN NEED

1 . A method for treating recurrent diarrhea disease in a veterinary subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of hemp extract.

2 . The method of claim 1 , wherein the veterinary subject is a primate.

3 . The method of claim 2 , wherein the primate is a non-human primate.

4 . The method of claim 3 , therein the non-human primate is a macaque.

5 . The method of claim 1 , wherein the recurrent diarrhea disease comprises idiopathic diarrhea.

6 . The method of claim 1 , wherein the hemp extract is administered orally.

7 . The method of claim 1 , wherein the hemp extract is administered in the form of a chew, a marshmallow, a gummy, or via syringe.

8 . The method of claim 1 , wherein the hemp extract is administered at a dosage of about 2 mg/kg, about 4 mg/kg, or about 8 mg/kg.

9 . The method of claim 1 , wherein the hemp extract is administered until the veterinary subject has a stool score of ≤2 for 3 days or for 21 days.

10 . The method of claim 1 , wherein the hemp extract is administered once a day, twice a day, three times a day, or four times a day.

11 . A method for treating inflammation, noise aversion, pyoderma, atopy, lameness, or arthritis or promoting wound healing in a veterinary subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of hemp extract.

12 . The method of claim 11 , wherein the veterinary subject is a dog, a horse, or a rabbit.

13 . The method of claim 11 , wherein the hemp extract comprises CBD, CBDA, CBG, CBGA, or a combination thereof.

14 . The method of claim 11 , wherein the hemp extract modulates neutrophil function, generation of reactive oxygen species, phagocytosis, eicosanoid concentrations, chemotaxis, cytokine production, and/or fibroblast response.

15 . (canceled)

16 . (canceled)

17 . The method of claim 11 , wherein the noise aversion is a phobia or wherein the noise aversion is to fireworks or thunderstorms.

18 - 30 . (canceled)

31 . The method of claim 11 , wherein the hemp extract is administered topically or orally.

32 - 51 . (canceled)

52 . A method for treating a neural condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of hemp extract.

53 . The method of claim 52 , wherein the subject is a human or a veterinary subject.

54 . (canceled)

55 . The method of claim 52 , wherein the neural condition comprises a traumatic neural injury or a degenerative neural disease.

56 . The method of claim 52 , wherein the hemp extract comprises THCA.

57 - 63 . (canceled)

64 . The method claim 1 , wherein the hemp extract comprises:

cannabidiol; and

cannabidiolic acid;

wherein the ratio of cannabidiol to cannabidiolic acid is about 0.1:1 to about 1:0.1.

65 . The method of claim 64 , wherein the hemp extract further comprises:

cannabigerolic acid;

Δ9-tetrahydrocannabinol; and

cannabichromene.

66 - 80 . (canceled)

81 . The method of claim 1 , wherein the hemp extract is formulated in a carrier.

82 . The method of claim 81 , wherein the carrier is selected from the group consisting of hemp seed oil, linseed oil, olive oil, fish oil, salmon oil, coconut oil, catnip oil, sesame oil, MCT oil, and grapeseed oil.

83 - 85 . (canceled)

86 . The method of claim 1 , wherein the hemp extract comprises lecithin.

87 . The method of claim 86 , wherein the lecithin is sunflower lecithin.

88 - 106 . (canceled)

107 . The method of claim 1 wherein the hemp extract is administered in a dosage form comprising one or more pharmaceutically acceptable additives, flavoring agents, surfactants, and adjuvants.

108 - 129 . (canceled)

130 . The method of claim 107 , wherein the dosage form is formulated as a chew for oral administration.

131 - 161 . (canceled)